Sol-Gel Technologies Ltd. Share Price Börse Stuttgart

Equities

4SG

IL0011417206

Biotechnology & Medical Research

Delayed Börse Stuttgart 03:07:08 26/06/2024 pm IST 5-day change 1st Jan Change
0.785 EUR +10.56% Intraday chart for Sol-Gel Technologies Ltd. -8.97% -34.26%

Financials

Sales 2024 * 5M 4.68M 418M Sales 2025 * 7.74M 7.24M 647M Capitalization 25.07M 23.46M 2.09B
Net income 2024 * -23M -21.52M -1.92B Net income 2025 * -16M -14.97M -1.34B EV / Sales 2024 * 5.02 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.24 x
P/E ratio 2024 *
-1.08 x
P/E ratio 2025 *
-1.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart
Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq MT
Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024 CI
HC Wainwright Adjusts Sol-Gel Technologies Price Target to $6 From $9, Maintains Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sol-Gel Technologies Ltd. and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize Twyneo® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director CI
Transcript : Sol-Gel Technologies Ltd. - Special Call
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study CI
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Sol-Gel Technologies to $12 From $19, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $7 From $9, Maintains Strong Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Latest transcript on Sol-Gel Technologies Ltd.

1 week-8.97%
Current month+12.70%
1 month+0.71%
3 months-27.92%
6 months-36.61%
Current year-34.26%
More quotes
1 week
0.71
Extreme 0.71
0.83
1 month
0.63
Extreme 0.63
0.83
3 years
0.49
Extreme 0.492
11.20
More quotes
Managers TitleAgeSince
Founder 62 28/97/28
Director of Finance/CFO 56 01/17/01
Chief Operating Officer 48 01/10/01
Members of the board TitleAgeSince
Director/Board Member 55 26/23/26
Director/Board Member 50 13/18/13
Chairman 69 01/14/01
More insiders
Date Price Change
26/24/26 0.785 +10.56%
25/24/25 0.71 -2.07%
24/24/24 0.725 -12.12%
21/24/21 0.825 +8.55%
20/24/20 0.76 0.00%

Delayed Quote Börse Stuttgart, June 26, 2024 at 03:07 pm IST

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9 USD
Average target price
6 USD
Spread / Average Target
+566.67%
Consensus